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Plants are known to have many secondary metabolites and phytochemical compounds
which are highly explored at biochemical and molecular genetics level and exploited
enormously in the human health care sector. However, there are other less explored
small molecular weight proteins, which inhibit proteases/proteinases. Plants are good
sources of protease inhibitors (PIs) which protect them against diseases, insects,
pests, and herbivores. In the past, proteinaceous PIs were considered primarily as
protein-degrading enzymes. Nevertheless, this view has significantly changed and PIs
are now treated as very important signaling molecules in many biological activities
such as inflammation, apoptosis, blood clotting and hormone processing. In recent
years, PIs have been examined extensively as therapeutic agents, primarily to deal with
various human cancers. Interestingly, many plant-based PIs are also found to be effective
against cardiovascular diseases, osteoporosis, inflammatory diseases and neurological
disorders. Several plant PIs are under further evaluation in in vitro clinical trials. Among
all types of PIs, Bowman-Birk inhibitors (BBI) have been studied extensively in the
treatment of many diseases, especially in the field of cancer prevention. So far, crops
such as beans, potatoes, barley, squash, millet, wheat, buckwheat, groundnut, chickpea,
pigeonpea, corn, and pineapple have been identified as good sources of PIs. The PI
content of such foods has a significant influence on human health disorders, particularly
in the regions where people mostly depend on these kind of foods. These natural PIs
vary in concentration, protease specificity, heat stability, and sometimes several PIs
may be present in the same species or tissue. However, it is important to carry out
individual studies to identify the potential effects of each PI on human health. PIs in plants
make them incredible sources to determine novel PIs with specific pharmacological and
therapeutic effects due to their peculiarity and superabundance.
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INTRODUCTION
Protease inhibitors (PIs) are well known as one of the prime candidates to have numerous
applications in biotechnology and medicine. These are very important tools for better
interpretation of basic principles of protein interactions and the designing of new compounds for
the control of pathologic processes and many diseases (Lingaraju and Gowda, 2008). More than
Srikanth and Chen Plant Protease Inhibitors in Therapeutics
half of the world’s population still depends completely on plants
and their medicinal products. Until now, plants have served
as starting raw materials for numerous drugs on the market.
From ancient time, plant extracts containing proteolytic enzymes
have been used in traditional medicine (De Feo, 1992). In
Ayurvedic, Homeopathy, Unani and even in Allopathic systems,
medical practitioners, and producers suggest and use several
medicines that are prepared from whole plants or plant parts or
phytochemicals such as secondary metabolites. Unlike primary
and secondary metabolites which comprise of an array of several
thousands of compounds, there are other compounds which are
still less explored among plant natural products, particularly the
proteins of low molecular weight. Protease inhibitors are among
the most important groups of such proteins. Similar to animals
and micro organisms, plants also contain several different types
of protease inhibitors.
It has been reported that the occurrence rates of breast,
colon, and prostate cancer are low in a population consuming
a higher amount of seeds like beans, maize and rice (Correa,
1981). There are many lines of evidence from in vitro, in vivo,
epidemiological and clinical trial data that demonstrate a plant-
based diet decreasing the risk of chronic diseases, cancer in
particular (Hasler, 1998). Block (1992) reported a review of
200 epidemiological studies which indicated that the cancer
possibility in people who ate more fruits and vegetables was
only one-half of that in those who ate a few of these foods.
Thus, good nutrition is a recognized key to disease prevention.
Also, health professionals are gradually recognizing the role of
phytochemicals in disease prevention and health promotion.
Recently, the molecular basis of disease prevention by nutritional
involvement has been under scientific consideration whereby
in the past, food intake has shown the ability to influence
the initiation or progression of chronic diseases (Dirsch and
Vollmar, 2001; Losso, 2008). Nowadays dietary factors have
also attracted attention as cancer prevention agents due to
their pharmacological safety. The abundance of plants can be
used either as raw materials “as it is” or processed further to
generate concentrated bioactive components with therapeutic
action like flavonoids and phenolic acids that comprise powerful
anti-oxidant activities (Pietta, 2000; Lizcano et al., 2010).
Food intake shows a strong influence on health (Losso,
2008). Instead of pills, functional foods can be consumed as
part of a normal diet. Hence, plant protease inhibitors (PPIs)
fit the definition of a functional food. Many researchers have
classified these plant protease inhibitors into families such as
Bowman-Birk, Kunitz, Potato I, Potato II, Serpine, Cereal,
Rapeseed, Mustard, and Squash (Laskowski and Qasim, 2000;
De Leo et al., 2002). Naturally occurring PIs are abundant in
legume seeds. Serine protease Bowman-Birk inhibitors (BBI)
and Kunitz-type inhibitors (KTI) have been studied extensively
as compared to the other in these legumes (Ryan, 1990).
These families differ in their mass, cysteine content, and
the number of reactive sites (Lingaraju and Gowda, 2008).
BBIs, which molecular weights range from 8000–10000 Da,
are double-headed serine protease inhibitors with 71 amino
acids and 7 disulphide bonds (Odani and Ikenaka, 1973). Each
BBI has two functional active sites on opposite sides of the
molecule, which inhibits both trypsin and chymotrypsin-like
proteases (Clemente et al., 2011). Whereas KTIs are 8000–
22,000 Da proteins with two disulphide linkages and a single
reactive site of trypsin (Laskowski and Qasim, 2000). Among
all, BBI is identified as a suitable protein to work with, in
terms of handling, resistance to temperature extremities and
acidification (Fields et al., 2012). Naturally occurring plant based
BBI is considered as a therapeutically significant candidate in
the treatment of multiple diseases, especially in the field of
cancer prevention (Fields et al., 2012). Perhaps its greatest
potential in therapeutic property lies in its ability to suppress
carcinogenesis irreversibly even during early stage (Wattenberg,
1992). Encouragingly, the amount of BBI that reaches the internal
organs after oral ingestion reaches the range that prevents
malignant transformation in vitro (Yavelow et al., 1985; Fields
et al., 2012). Several PPIs are under further evaluation in human
clinical trials.
Protease inhibitors designed for therapeutic applications are
quickly advancing due to the ever extending establishment of key
information provided by the protein chemists and enzymologists
working in this field. In this review, we focus on the role of
plant proteases and their inhibitors in human diseases, and on
the possible application of proteinaceous plant PIs as drugs. We
also will discuss the several criteria to be met before such drugs
are applicable to clinical trials.
ROLES OF PLANT PROTEASE INHIBITORS
IN HEALTH AND DISEASE CONTROL
The widespread distribution of protease inhibitors throughout
the plant kingdom is well known since 1938 (Ryan, 1973). In
general, these PIs comprises about 5–10% of the total content of
water-soluble proteins found in the seeds of dicots and monocots
of angiosperms and in gymnosperms (Mutlu and Gal, 1999).
However, the most well-studied protease inhibitors of plant
origin are from three main families namely, Fabaceae, Poaceae,
and Solanaceae (Richardson, 1991). Weder (1981) reported that
the seed protein of the legumes enriched with up to 6% of PIs,
whereas cereal contains about 10% of PIs (Pusztai, 1972). Later,
many studies have reported PIs found in other families such
as Malvaceae, Rutaceae, Poaceae and Moringaceae (Bijina et al.,
2011). These natural PIs mainly accumulate in tubers, seeds, and
leaves.
Medicinal plant biotechnology has emerged as a revolutionary
methodology which is useful to induce the formation and
accumulation of desirable compounds and eventually develop
the therapeutic product (Constabel, 1990). Therefore, it is
indispensable to select locally available edible plant species or
plant extracts that could practically be added to the available
drugs list, or even replace some expensive compounds that need
to be utilized in pharmaceutical preparations. The investigation
to search for PIs to combat several clinical disorders started
in early 1950’s (Vogel et al., 1968). For many years, several
researchers have isolated and purified these plant PIs from
different plant species and examined them as therapeutic agents
using in vitro methods. Many of those naturally found PIs
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were further characterized from different plant species which
mainly included trypsin from serine protease group which
have been tested for various diseases (Richardson, 1991; Tamir
et al., 1996; Majumdar, 2013). This review explains about PIs
of all earlier reported plant species that have been used as
therapeutic agents and tested against different diseases and
human disorders (Table 1; Murugesan et al., 2001; Neuhof et al.,
2003; Troncoso et al., 2003; Kobayashi et al., 2004; Lanza et al.,
2004; Clemente et al., 2005, 2012; Kim et al., 2005; Suzuki
et al., 2005; Capaldi et al., 2007; Banerjee et al., 2008; Tochi
et al., 2008; Caccialupi et al., 2010; Hsieh et al., 2010; Joanitti
et al., 2010; García-Gasca et al., 2012; Magee et al., 2012; de
Paula et al., 2012a; Borodin et al., 2013; Ferreira et al., 2013;
Rakashanda et al., 2013b; Clemente and Arques, 2014; Souza
et al., 2014) and future scope to search for new species, which
are as follows:
Ananas comosus (L.) Merr. (Pineapple)
Bromelain proteases from pineapple extracts (Fruit bromelain)
are clinically used as anti-inflammatory agents (Ammon, 2002;
Darshan and Doreswamy, 2004; Lemay et al., 2004) for colonic
inflammation, chronic pain, rheumatoid arthritis, soft tissue
injuries, and asthma (Izaka et al., 1972; Cooreman et al., 1976;
Taussig and Batkin, 1988; Kelly, 1996; Maurer, 2001; Jaber, 2002;
Hale et al., 2005). Similar folding and disulfide bond connectivity
were found to be shared in Bromelain inhibitor VI from
pineapple stem (Stem bromelain, BI-VI) with the Bowman-Birk
trypsin/chymotrypsin inhibitor from soybean (BBI-I) (Hatano
et al., 1996). It is essentially a group of sulfhydryl proteolytic
enzymes that includes a variety of cysteine proteases (Tochi
et al., 2008). Along with protease inhibitors, it also encompasses
peroxidases, acid phosphatase, organically bound calcium and
remains stable over a wide range of pH 2–9 (Hatano et al.,
1996; Tochi et al., 2008). Even though, both stem bromelain
and fruit bromelain are single-chain glycosylated enzymes, stem
bromelain has low proteolytic ability and specificity for peptide
bonds compared to fruit bromelain. Similarly, the molecular
weight ranges for stem bromelain and fruit bromelain are 26–37
kDa and 24.5–32 kDa respectively (Grzonka et al., 2007; Gautam
et al., 2010; Kumar et al., 2011).
It is reported that bromelain with its proteolytic nature
is well absorbed orally in a dose-dependent manner (Hatano
et al., 1996). Proteolytic activity of bromelain has been
shown to play a minor part in pharmacological activity while
other factors of it, such as immune-modulatory, hormone-like
properties, fibrinolytic activity and uncharacterized components
such as CCS and CCZ compliments also contributes toward
its pharmacological activity (Tochi et al., 2008). However, it
is necessary to investigate further on these uncharacterized
components. Investigating how the uncharacterized components
can be incorporated into daily food is important to determine if
it is safe and non-toxic (Tochi et al., 2008).
Bauhinia bauhinioides (Mart.) J.F. Macbr.
and Bauhinia rufa (Bong.) Steud.
Bauhinia seeds are rich in serine and cysteine proteases inhibitors
(Oliva and Sampaio, 2008; Oliva et al., 2010, 2011). Oliva et al.
(1999) isolated the Bauhinia bauhinioides kallikrein inhibitor
(BbKI) from seeds of B. bauhinioides, which is a 18-kDa protein
with a similar primary structure to that of other plant Kunitz-
type inhibitors but is devoid of disulphide bridges. BbKI was
able to inhibit plasma kallikrein, plasmin, bovine trypsin, bovine
chymotrypsin, porcine pancreatic kallikrein, and murine plasma
kallikrein (Oliva et al., 1999). Nakahata et al. (2006) isolated
another inhibitor from Bauhinia rufa and named it as BrTI (B.
rufa trypsin inhibitor) that can inhibit human plasma kallikrein
(Ki app = 14 nM) in addition to trypsin (Ki app = 2.9 nM).
Kunitz-type protease inhibitor from B. bauhinioides and
B. rufa are reported to reduce the edema formation in
isolated perfused rabbit lung (Neuhof et al., 2003). Kunitz-type
Inhibitor BbCI (10(-5)M) from B. bauhinioides significantly
decreased the pulmonary edema in isolated perfused rabbit
lungs caused by activated neutrophils via release of elastase
to the same degree as by eglin C (10(-5)M) from Hirudo
medicinalis, which was used as a reference (Neuhof et al., 2003).
Kallikreins play an important role in the establishment of a
common prostate cancer. RGD/RGE motifs of the inhibitor
BrTI from Bauhinia rufa is included into rBbKIm to form
the recombinant B. bauhinioides kallikreins (Ferreira et al.,
2013). This rBbKIm inhibited trypsin (Ki app = 1.6 nM),
chymotrypsin (Ki app = 7.4 nM), and human plasma kallikrein
(Ki app = 3.6 nM). Also, it was reported that the viability of
fibroblasts was not affected when rBbKIm inhibited the cell
viability of DU145 and PC3 prostate cancer cells (Ferreira et al.,
2013).
Cicer arietinum L. (Chickpea)
Protease inhibitor concentrates extracted from Chickpea seeds
which enriched in BBI-type PIs exhibited inhibitory activity
against chymotrypsin (Magee et al., 2012). Viability of MDAMB-
231 breast cancer and PC-3 and LNCaP prostate cancer cells were
inhibited significantly by Chickpea Bowman-Birk-type protease
inhibitor (molecular weight ∼8 kDa) at all concentrations tested
(25–400 µg/ml; Magee et al., 2012). The study also suggested
that chickpea PIs may contain same anticancer properties like
soybean BBI and hence deserves further study as a potential
chemopreventive agent (Magee et al., 2012).
Coccinia grandis (L.) Voigt.
The Coccinia grandis protease inhibitors (CGPI) is a protein
of 14.3 kDa isolated from its leaves. CGPI showed a highest
inhibitory activity against both bovine pancreatic trypsin and
chymotrypsin. The antimicrobial activity of thses CGPIs has
been reported by Satheesh andMurugan (2011). CGPIs exhibited
significant growth inhibitory effect on colon cell lines via
dose-dependent manner. These CGPIs also inhibited mycelial
growth and sporulation of pathogenic microbial strains such
as Staphylococcus aureus, Klebsiella pneumonia, Escherichia
coli, Proteus vulgaris, Bacillus subtilis and pathogenic fungus
Mucorindicus, Candida albicans, Pencilliumnotatum, Aspergillus
flavus, and Cryptococcus neoformans (Satheesh and Murugan,
2011). PIs-treated fungus showed a significant shrinkage of
hyphal tips. These results indicate that the PIs extracted from
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C. grandis will be an excellent compound to develop oral or other
anti-infective agents.
Elusine coracana Gaertn. (ragi)
Generally in many regions, finger millet or ragi is considered
as a staple food crop for its excellent nutritional qualities, long
storage capability, and medicinal properties. Sen and Dutta
(2012) reported that purified ragi (Elusine coracana) is a 14
kDa bifunctional inhibitor (RBI), a member of cereal trypsin/α-
amylase inhibitor family that simultaneously inhibits α-amylase
and trypsin forming a ternary complex (Maskos et al., 1996).
Its primary structure is a monomeric protein of 122 amino
acids containing five intramolecular disulfide bonds (Campos
and Richardson, 1983). The RBI reduced cellular proliferation
and induced apoptosis of chronic myeloid leukemia cell, K562.
These purified RBI exhibited cytotoxicity toward K562 chronic
myeloid leukemia cells, but not against normal human peripheral
blood mononuclear cells. This investigation may provide a future
preventive as well as a natural therapeutic solution for chronic
myeloid leukemia.
Enterolobium contortisiliquum (Vell.)
Morong
It is a flowering tree in the pea family, Fabaceae. The purified
Enterolobium contortisiliquum Trypsin Inhibitor (EcTI) is a 20
kDa protein of a Kunitz-type inhibitor from the seeds. EcTI
inhibited the activity of trypsin, chymotrypsin, plasma kallikrein,
and plasmin (Nakahata et al., 2011). The effects of a EcTI
on adhesion, migration, and invasion of gastric cancer cells
were reported by de Paula et al. (2012a). EcTI was shown to
reduce the expression without affecting the fibroblasts upon
adhesion and interrupt the cellular organization of molecules
such as integrin β1, cortactin, MT1-MMP,MMP-2, andN-WASP,
which are involved in the establishment and maturation of
invadopodia. EcTI decreased Src-FAK signaling thereby inhibited
the adhesion, migration and cell invasion (de Paula et al., 2012b).
It was clear from the study that EcTI inhibited the invasion of
gastric cancer cells by manipulating the integrin-dependent cell
signaling pathways. Furthermore, Nakahata et al. (2011) reported
the inhibition of human cancer cell lines, such as HCT116 and
HT29 (colorectal), K562 and THP-1 (leukemia), SkBr-3 and
MCF-7 (breast), as well as on human primary fibroblasts and
human mesenchymal stem cells (hMSCs) upon treatment with
EcTIs. Data indicates that the EcTI is an important tool in the
studies of tumor cell development and distribution as it prevents
proMMP activation, and is cytotoxic against tumor cells without
disturbing normal tissue.
Fagopyrum sculentum Moench
(Buckwheat)
A buckwheat inhibitor (BWI)-1 protein extracted from common
buckwheat seeds with a molecular weight of 7.7 kDa (Dunaevsky
et al., 1997). BWI-1 is from the potato inhibitor I family which
can inhibit trypsin, chymotrypsin, and subtilisin, whereas BWI-
2a is a new PI, homologous to the vicilin family that can only
inhibit trypsin (Lim, 2013). The inhibitory activity of BWI-1 and
BWI-2a against T-acute lymphoblastic leukemia (T-ALL) cells,
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such as JURKAT and CCRF-CEM and human normal blood
lymphocytes has been reported previously (Park and Obha, 2004;
Lim, 2013). These two inhibitors induce apoptosis in these cells
with DNA fragmentation.
Glycine max (L.) Merr. (Soybean)
The seeds of Glycine max possess both BBI and KTI. Its BBI
is an 8 kDa protein and is able to reduce the proteolytic
activities of trypsin, chymotrypsin, elastase, cathepsin G, and
chymase, serine protease-dependent matrix metalloproteinases,
urokinase protein activator, mitogen activated protein kinase,
and PI3 kinase, and upregulates connexin 43 (Cx43) (Losso,
2008). Whereas the molecular weight of KTI is approximately
22 kDa. A concentrated protein extract of soybean, known as
Bowman-Birk inhibitors concentrate (BBIC) which is enriched
with BBI, is a present investigational new drug. The name
of the family Bowman-Birk inhibitors is coined after D. E.
Bowman and Y. Birk, who identified and characterized the typical
member of this family, the soybean inhibitor from soybean
(Glycine max; Bowman, 1946; Birk, 1961). In rodents, soybean
BBI treatment has a potent suppressive effect on colon and
anal gland inflammation, following exposure to carcinogenic
agents (Billings et al., 1990). Soybean BBI reduced the initiation
and regularity of colorectal tumors at low concentrations of
10 mg/100 g diet in the dimethylhydrazine (DMH) rat model,
without any adverse effect on the animal growth or organ
physiology (Kennedy et al., 2002). This suppressive effect on
the colorectal tumor development was disappeared upon the
reduction of BBI inhibitory activity, indicating that the BBI
inhibitory activity against serine proteases may be necessary
for the chemopreventive properties (Figure 1). The protease
activities, which plays a major role in tumorigenesis, are
deregulated in colorectal cancer and neoplastic polyps (Chan
et al., 2010).
Ware et al. (1999) reported that soybean BBI inhibited the
proteases of inflammation-mediating cells and suppressed the
superoxide anion radical production from the immunocytes.
This study also indicated that BBIC can positively influence
the dextran sulfate sodium-treated mice, which in turn useful
in treating the human inflammatory bowel diseases, mainly
ulcerative colitis. Another study reported that BBI is an anti-
carcinogenic serine protease inhibitor that may obstruct the
protease activity of prostate-specific antigen (PSA) and the
development of human prostate cancer xenografts in nude mice
(Wan et al., 1999b).
The role of soybean BBI in suppressing the development
of activated oxygen species from prostate cancer cells (Sun
et al., 2001), and in triggering DNA repair via a p53-dependent
mechanism have been reported (Kennedy et al., 2002). In the
recent studies, BBIC has prevented the growth of prostate tumors
by its antiproliferative activity through stimulation of connexin
43 expressions in transgenic rats (McCormick et al., 2007; Tang
et al., 2009).
The suppressive activity of soybean BBI, on HT29 colon
cancer cells, compared with CCD-18Co cells of non-malignant
colonic fibroblast was studied by Clemente et al. (2010). The
study indicated that the BBI treatment in a dose-dependent
manner, blocked the G0-G1 phase to disrupt the cell cycle
distribution pattern of HT29 colon cancer cells. Chen et al.
(2005) reported the BBI as a potential inhibitor which inactivated
the MCF7 cancer cells both in vitro and in vivo by inhibiting
26S proteasomal chymotrypsin-like activity. The study also
indicated that the BBI arrested the growth of MCF7 cells at
G1/S phase, by accumulating MKP-1 causing interruption in
the ubiquitin-proteasome pathway which resulted in suppressed
ERK1/2 activity. Being a potential chemotherapeutic drug, BBI
obstructs the cell proliferation and viability at different stages
of cancer development. Hence, the BBI involving proteasome
inhibition is considered as a new mechanism which may be a
potential reason for its chemopreventive properties. Eventually,
the study on soybean BBI proteins has provided an information
on the therapeutic interference of soybean BBI for breast cancer
treatment.
Kobayashi et al. (2004) studied the effects of soybean trypsin
inhibitor (SBTI) on the enzymatic activity of extracellular uPA
and signal transduction mechanisms that are involved in its
expression and incursion into HRA human ovarian cancer
cells. Authors concluded that KTI could stop cell invasiveness
by reduction of uPA signaling instead of BBI although the
mechanisms of KTI may not be the same as those of Bikunin.
BBI inhibited M5067 ovarian sarcoma by increasing expression
of tumor-suppressor molecules Cx43 (Suzuki et al., 2005).
Oral administration has been recognized as a possible
and cost-effective approach to reducing cancer morbidity
and mortality by inhibiting precancerous events before the
occurrence of clinical disease (Prasain and Barnes, 2007).
Hsieh et al. (2010) found that lunasin is actually the bioactive
cancer preventive agent in BBIC and BBI simply protects
lunasin from digestion when soybean and other seed food
are eaten by a human. Currently, the rising of breast cancer
cases urged to identify novel compounds that can be utilized
as preventive or therapeutic agents. Evidence is shown from
animal experiments, epidemiological studies, and human surveys
of people consuming a soy-rich diet exhibited lower disease
occurrence andmortality from breast cancer which leads to more
research on various compounds from soy that can prevent breast
cancer (Adlercreutz et al., 1995; Banerjee et al., 2008; Hernández-
Ledesma et al., 2009). Consuming such anticancer compounds
daily could be an alternative to chemotherapy, which is safe
to the physiology of normal tissue and prevents initiation of
micro tumors (Béliveau and Gingras, 2007; de Kok et al., 2008).
Furthermore, it is important to assess the possible risks and
advantages of phytochemicals to human health by understanding
the physiological behavior of these compounds after oral
intake which includes absorption, distribution, metabolism and
excretion (Prasain and Barnes, 2007).
Borodin et al. (2013) reported that the effect of both proteins,
soybean SBTI and aprotinin, on coagulation and thrombocyte
hemostasis by in silico and in vitro methods and demonstrated
the inhibition of blood clotting, fibrinolysis and platelet
aggregation (Figure 5). These outcomes were accomplished by
increased prothrombin time, activated partial thromboplastin
time, activated clotting time, thrombin time as well as prevention
of fibrinolysis.
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FIGURE 1 | Crystal structure of cancer chemopreventive Bowman-Birk inhibitor from Soybean in a ternary complex with bovine trypsin (PDB id: 1d16r)
(Koepke et al., 2000).
Hordeum vulgare L. (Barley)
In 1970’s, a group of ∼43 kDa proteins from mature grains
of barley (Hordeum vulgare L.) were identified as members of
the serpin superfamily (Hejgaard et al., 1985). There are three
mostly recognized barley serpin subfamilies: BSZ4, BSZ7, and
BSZx. Barley serpins are effective, irreversible inhibitors of serine
proteases of the chymotrypsin family. The Barley serpin, BSZx
inhibits both chymotrypsin and trypsin at overlapping reactive
sites (Dahl et al., 1996a). BSZx serpin interacts with a range
of serine proteases from human plasma, leukocytes, pancreas,
a fungal trypsin and three subtilisins (Dahl et al., 1996b). The
study indicated that BSZx inhibitors which inhibited trypsin and
chymotrypsin are also capable to inhibit coagulation factors such
as thrombin, plasma kallikrein, Factor VIIa and Factor Xa.
Ipomoea batatas L. (Sweet Potato)
The anti-proliferative effect and the mechanism of a 22 kDa
trypsin inhibitor (TI) protein from sweet potato (Ipomoea
batatas (L.)) storage roots on NB4 promyelocytic leukemia cells
was reported by Huang et al. (2007). TI arrested cell cycle at
the G1 phase as determined by flow cytometry analysis and
apoptosis as shown by DNA laddering. TI-induced cell apoptosis
involved p53, Bcl-2, Bax, and cytochrome c protein in NB4
cells. P53 and Bax proteins accumulated, and antiapoptotic
molecule Bcl-2 decreased in the tested cells in a time-dependent
manner during TI treatment. The study indicated that TI
stimulates the apoptosis of NB4 cells by blocking the cell
growth and activating the pathways of caspase-3 and -8
cascades.
Lavatera cashmeriana Camb.
It belongs to the Malvaceae family, which is indigenous to
Kashmir valley, has incredible medicinal values. For many
years, its plant parts are being utilized to cure cold and
sore throat (Rakashanda et al., 2013a). Lavatera cashmeriana
protease inhibitors (LC-pi I, II, III, and IV) were extracted
from its seeds and are considered as a Kunitz type of
inhibitor based on their molecular size (Rakashanda et al., 2012,
2013a). These protease inhibitors were able to inhibit trypsin,
chymotrypsin, and elastase. Four serine protease inhibitors
appeared as 20.9, 14.1, 16.8, and 7.9 kDa peaks in gel
filtration and 10, 14, 16, and 7 kDa bands by SDS PAGE.
Representing that LC-pi I includes two similar subunits of
10 kDa. LC-pi I tested against Klebsiella pneumoniae and
Pseudomonas aeruginosa which showed strong antibacterial
activity but was less active against Escherichia coli (Figure 5).
However, all four inhibitors demonstrated the in vitro anticancer
activity on THP-1 (leukemia), NCIH322 (lung), and Colo205,
HCT-116 (colon). Among all, LC-pi I and II were treated as
potential anticancer agents (Rakashanda et al., 2013b). Moreover,
a strong inhibitory effect of LC-pi I was exhibited in in vitro
conditions on the initiation of the prostate (PC-3) and breast
(MCF-7) cancer cells lines because of its protease inhibitor
activity of trypsin, chymotrypsin, and elastase (Rakashanda et al.,
2013a).
Lens culinaris L. (Lentil)
Ragg et al. (2006) reported the isolation of a lentil (Lens
culinaris, L., var. Macrosperma) seed trypsin inhibitor (LCTI)
and its functional and structural characterization. LCTI is a 7.4
kDa double-headed trypsin/chymotrypsin inhibitor (Figure 2).
Further, Caccialupi et al. (2010) isolated a full-length cDNA,
encoding a BBI from lentil seeds. The effects of this mature
BBI on the growth of human colon adenocarcinoma HT29 and
colonic fibroblast CCD-18Co cells were evaluated. LCTI was able
to inhibit the growth of such cells at concentrations as low as 19
µmol/L, in a concentration-dependent manner without affecting
the CCD-18Co cells.
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FIGURE 2 | IBB_LENCU—Bowman-Birk type protease inhibitor
monomer from Lens culinaris (PDB id: 2aih).
Macrotymola axillare (E. Mey.) Verdc.
(Perennial Horse Gram)
Joubert et al. (1979) isolated and characterized two protease
inhibitors, DE-3 and DE-4 fromMacrotyloma axillare seeds. The
amino acid sequences of two protease inhibitors were compared
with the known sequences of the BBIs which resulted in 67%
homology and corresponding properties of the BBI double-
headed protease inhibitor group. Each of them comprise 76
amino acid residues including 14 half-cystine residues. BBI from
the M. axillare worked against inflammation and initiation of
pre-neoplastic lesions in the induced DMH mouse model as
reported by de Paula et al. (2012b). In this study, the potential
ability of BBI preparations was examined for the prevention
of colorectal neoplasia caused by intraperitoneal injections of
1,2-dimethylhydrazine (DMH) by using 30mg/kg dosage over a
period of 12 weeks. Histopathological variations consistent with
tumor development, increased CD44 expression and proteasome
peptidase activities were exhibited by the DMH-treated mice.
It is demonstrated that the BBI inhibited both lysosomal and
proteasome-dependent proteolytic pathways through which it
could prevent the development of pre-neoplastic lesions.
Medicago scutellata L. (Snail Medic)
Medicago scutellata L. (Snail medic) seeds stores a significantly
higher content of a trypsin inhibitor (MsTI ) compared to
Medicago species. MsTI belongs to the BBI family of serine
proteases and exhibited a highest sequence homology with the
soybean BBI (Catalano et al., 2003). It consists of 62 residues
corresponding to a molecular mass of 6.9 kDa. Catalano et al.
(2003) reported the anticarcinogenic BBI, which is a high-
resolution three-dimensional structure purified from snail medic
seeds (Medicago scutellata) (MSTI) (Figure 3). Later, Capaldi
et al. (2007) reported the ternary complex structure of the
BBI that is purified from snail medic seeds (MSTI) and two
molecules of bovine trypsin. The effects of MsTl on cell killing
induced by cisplatin in MCF7 human breast carcinoma cells
and HeLa cervical carcinoma cells were evaluated by Lanza
et al. (2004). After 24 h of MsTI treatment with cell culture
medium, resulted in increased cisplatin-induced cytotoxicity and
reduced the clonogenic survival of MCF7 and HeLa cells in a
dose-dependent manner. In comparison with the similar ternary
complex of the SBTI, this model shows very little differences
in the polypeptide chain of the trypsin binding sites. The area
between Asp 26 and His 32 of the MSTI has the largest difference
whereby the soybean inhibitor has an extra Leu inserted in
position 29 (Catalano et al., 2007).
Moringa oleifera Lam.
It belonging to the family Moringaceae, recorded high level of
protease inhibitor activity (92%) against trypsin (Bijina et al.,
2011). PI extracted from M. oleifera is a small protein with a
molecular weight of 23.6 kDa. Its molecular mass and and the
disulphide content of the polypeptide indicated that Moringa PI
belongs to the Kunitz type of serine protease inhibitor family
(Bijina et al., 2011).M. oleifera grows well throughout the tropics
and almost every part of the plant is of value as food. The flowers,
leaves, and roots are used in folk remedies for the treatment of
tumors and the seeds for abdominal tumors. The bark is regarded
as antiascorbic and exudes a reddish gum with properties of
tragacanth is sometimes used for diarrhea. Roots are bitter and
act as a tonic to the body and lungs. They are used as an
expectorant, mild diuretic, stimulant in paralytic aﬄictions, in
epilepsy, and in hysteria (Hartwell, 1971). Moreover, there are
a few low molecular weight bioactive compounds present in
Moringa seeds which exhibited bactericidal, fungicidal, immune
suppressive activities (Mahajan and Mehta, 2010) and some anti-
inflammatory agents (Caceres et al., 1991; Cheenpracha et al.,
2010). Moringa PI is the potential source for the development
of a new drug against thrombin, elastase, chymotrypsin, trypsin,
cathepsin, and papain in pharmaceutical industries (Bijina et al.,
2011). Furthermore, these PIs could also be used as a seafood
preservative against proteolysis and in other biotechnological
applications.
Phaseolus acutifolius A. Gray (Tepary
Bean) and Phaseolus vulgaris L.
Bowman-Birk PI from Tepary bean (TBPI) seeds with anti-
trypsin and antichymotrypsin activities was isolated and
characterized by Campos et al. (1997). García-Gasca et al.
(2012) again purified and characterized 7 kDa TBPI as
described by Campos et al. (1997). However, this purified
TBPI did not show cytotoxicity but it was responsible for
the increase in cell adhesion and decrease in extracellular
matrix degradation in cell culture which leads to a decreased
in vitro cell invasion capacity and suppression of matrix
metalloproteinases-9 activity simultaneously. According to this
study, the Tepary bean seeds contain minimum two separate
groups of bioactive proteins with anticancer properties (García-
Gasca et al., 2012). The study also reported that cells treated
with TBPI diminished their invasive ability most probably due
to the suppression of MMP2 and MMP9. Sun et al. (2010)
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FIGURE 3 | Bowman-Birk inhibitors of Medicago scutellata. (A) IBB_MEDSC-Bowman-Birk type protease inhibitor (PDB id: 1mvz). (B) The anticarcinogenic
Bowman-Birk inhibitor from snail medic (Medicago scutellata) seeds complexed with bovine trypsin (Capaldi et al., 2007).
isolated and purified two trypsin inhibitors of each with a
molecular mass of 16 kDa from Phaseolus vulgaris cv “White
Cloud Bean.” Both of these inhibitors showed an antiproliferative
activity toward Leukemia L1210 albeit with a little variance in
potency, but there was little activity toward lymphoma MBL2
cells.
Pisum sativum L. (Pea)
The crystal structure of the Pisum sativum (PsTI) isoform was
determined by molecular replacement at 2.7A resolution using
the X-ray coordinates of the soybean inhibitor as a search
model (Li de la Sierra et al., 1999). Protease inhibitors, rTI1B,
and rTI2B from P. sativum L. (Pea) are homologous to BBI
with molecular mass range 7–9 kDa, but differ in inhibitory
activity, on the growth of human colorectal adenocarcinoma
HT29 cells in vitro (Clemente et al., 2005, 2012). The
rTI1B proved to be active against trypsin and chymotrypsin,
whereas the related mutant protein was inactive against both
serine proteases. The proliferation of HT29 colon cancer cells
was notably affected by rTI1B in a dose-dependent manner,
whereas the inactive mutant did not show any significant
activity on cell growth of colon cancer. Likewise, none of the
recombinant proteins affected the growth of non-malignant
colonic fibroblast CCD-18Co cells. From the findings, it was clear
that serine proteases are important candidates in investigating
the potential cancer preventive trait of BBI in the initial stages
of colorectal cancer (Clemente et al., 2012; Clemente and Arques,
2014).
Peltophorum dubium (Spreng.) Taub.
Troncoso et al. (2003) isolated a trypsin inhibitor, PDTI of
molecular mass range 20–22 kDa from Peltophorum dubium
seeds. The amino-terminal sequences of PDTI were the same as
Kunitz-type soybean trypsin inhibitor (SBTI). Both PDTI and
SBTI triggered apoptosis of Nb2 rat lymphoma cells via reducing
viability, DNA fragmentation, DNA hypodiploidy and caspase-
3-like activity. However, they did not damage normal mouse
splenocytes or lymphocytes but caused apoptosis of concanvalin
A-stimulated mouse lymphocytes (Troncoso et al., 2003). Many
findings reported about the anti-proliferative effect and apoptosis
in human leukemia cells (JURKAT) via PDTI and SBTI activity.
In addition, human peripheral lymphocytes, stimulated with
phytohemagglutinin or not, are also sensitive to viability decrease
that is induced by SBTI (Troncoso et al., 2007).
Pseudostellaria heterophylla Rupr. &
Maxim. (Ginseng)
Wang and Ng (2006) isolated a 20.5 kDa trypsin inhibitor of
Kunitz-type with antifungal activity (Figure 5) and a new lectin
from roots of P. heterophylla. They exhibited a trypsin inhibitory
activity that is similar to soybean trypsin inhibitor. Antifungal
activity was also demonstrated toward Fusarium oxysporum like
sprotinin and Kunitz-type trypsin inhibitors from soybeans and
lima beans.
Solanum tuberosum L.
Although protease inhibitors are found in plants belonging to
different kinds of systematic groups, high levels of protease
inhibitors are often reported in many plants belonging to
the Solanaceae family (Plate et al., 1993). The effect of a
protease inhibitor extracted from potatoes (POT II) which
increase CCK release, on food intake was examined in 11
lean subjects by Hill et al. (1990). The findings suggested
that endogenous CCK may be important in the control of
food intake and that protease inhibition may have therapeutic
potential for reducing food intake. Several antimicrobial peptides
have been purified from potato tubers. As an example, a 5
kDa pseudothion of S. tuberosum (Pth-St1) was found to be
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active against bacterial and fungal pathogens of potato such as
Clavibacter michiganensis subspecies sepedonicus, Pseudomonas
solanacearum, and Fusarium solani. Trypsin or insect α-amylase
activities are not inhibited by Pth-St1 and it does not affect
cell-free protein synthesis or β-glucuronidase activity with true
thionins (Moreno et al., 1994). It was also found that Snakin-
1 (stSN1) and Snakin-2 (stSN2) are active against the fungal
pathogens, Clavibacter michiganensis subspecies sepedonicus and
Botrytis cinerea at concentrations <10 µM (Kim et al., 2009).
Patatin, a potato tuber storage protein, which was purified to
homogeneity, has antioxidant and antiradical activity (Liu et al.,
2003). Potamin-1 (PT-1), a stress-inducible trypsin inhibitor,
was also present in potato tubers (Ledoigt et al., 2006).
The potamin-1 (PT-1) trypsin-chymotrypsin protease inhibitor
(5.6 kDa) was found to be thermostable without potential
hemolytic activity but holds antimicrobial activity. It strongly
inactivated the pathogenic microbial strains such as Candida
albicans, Rhizoctonia solani, andClavibacter michiganense sub sp.
michiganinse (Kim et al., 2005).
Vicia faba L. (Field Bean)
A trypsin/chymotrypsin inhibitor with a molecular weight of
18 kDa was purified from seeds of Vicia faba L (Gupta et al.,
2000). Fernandes and Banerji (1995) tested the ability of the FBPI,
when administered by gavage, to subdue benzopyrene (BP)-
induced neoplasia of the forestomach of mice. The mice that
were treated with heat-inactivated FBPI showed similar tumor
multiplicity to the BP-treated group, indicating that inhibitory
capacity. These findings indicated the ability of FBPIs as effective
chemo-protectors against gastric cancer in animals and, possibly,
in humans as well. The purified FBPI has been found to
be quite similar to the Soybean-derived BBI in its properties
and anticarcinogenic potentials (Banerji and Fernandes, 1994;
Fernandes and Banerji, 1995, 1996). Skin carcinogenesis can
be effectively suppressed by topical treatment with a FBPI as
reported by Fernandes and Banerji (1996) and plasmin inhibitory
activity of FBPI can help to stop pulmonary metastasis of B16F10
melanoma cells systemically injected into BDF1 mice (Banerji
et al., 1998a). Banerji et al. (1998b) investigated the ability of
FBPI to stop ethylnittrosourea (ENU)-induced tumors of the
nervous system of Sprague-Dawley rats. Murugesan et al. (2001)
labeled the same FBPI with 99mTcO−4 to determine its capability
to identify tumors in tumor-bearing rat models when a neural
tumor incidence of 100% in the rats treated with heat-inactivated
FBPI confirmed that the tumor suppressor activity of FBPI is
related to its PI activity (Banerji et al., 1998b). This labeling was
done with Sn2+ as a reducing agent and the yield was 95% which
was stable for 2 h at ambient temperature. This study indicated
that 99mTcFBPI has the exact prospective for imaging gliomas
and probably other tumors as well. The study also indicated that
it was possible to label FBPI with radionuclides such as 186Rh
and 153Sm, which could also be used for the detection of tumors
particularly of glial origin in patients.
Vigna unguiculata L. (Black-Eyed Pea)
The Black-eyed pea Trypsin/Chymotrypsin Inhibitor (BTCI)
isolated and purified from Vigna unguiculata (Cowpea) seeds
is a natural PPI, and it belongs to the BBI family with two
different and independent reactive sites for trypsin (Lys26) and
chymotrypsin (Phe53) (Souza et al., 2014). BTCI is a globular
protein comprising 83 amino acid residues with seven disulfide
bonds and molecular weight of 9.1 kDa (Barbosa et al., 2007).
The effects of the BTCI (Figure 4), on the MCF-7 breast
cancer cells was reported by Joanitti et al. (2010). BTCI-induced
apoptosis, cell death due to morphological alterations of the cell
and lysosomemembrane permeation demonstrated via cytostatic
and cytotoxic findings. The anti-carcinogenic capabilities of BBI
and newly identified BTCI established a promising tool for drug
developments aimed to treat breast cancer. Recently, Souza et al.
(2014) reported the effects of a BTCI on proteasome 20S inMCF-
7 breast cancer cells and the catalytic activity of the purified 20S
proteasome from horse erythrocytes, as well as the structural
analysis of the BTCI-20S proteasome complex. Furthermore,
Mehdad et al. (2016) stated that BTCI significantly decreased
human breast adenocarcinoma cell viability by inhibiting the
activity of proteasome 20S, with an associated cytostatic effect
at the G2/M phase of the cell cycle and an increase in
apoptosis.
Numerous protease inhibitors have been isolated and
characterized from different plant species. PIs were isolated
from Scopolia japonica cultured cells and these were found to
have potential inhibitory activity against trypsin, chymotrypsin,
kallikrein, plasmin, and pepsin but could not inhibit pain using
synthetic or natural substrates (Sakato et al., 1975). Proteases
like papain from Carica papaya L. has been used in different
industrial processes including pharmaceutical process (Macalood
et al., 2013). BBI like inhibitors were also isolated from sunflower
(sunflower trypsin inhibitor-1; Luckett et al., 1999; Korsinczky
et al., 2001; Marx et al., 2003; Le˛gowska et al., 2010) and
peanut (Arachis hypogaea L.; Tur Sinal et al., 1972; Norioka
and Ikenaka, 1983; Suzuki et al., 1987). Protease inhibitors
belonging to the Kunitz inhibitor family has been purified
from pigeonpea (Cajanus cajan (L.)) PUSA 33 variety (Haq
and Khan, 2003). A red gram protease inhibitor (RgPI) was
extracted and purified from Cajanus cajan (Kollipara et al., 1994;
Prasad et al., 2010b). BBI type inhibitors were purified and
characterized from /in black gram (Vigna mungo (L.) Hepper)
(Prasad et al., 2010a).
Mustard trypsin inhibitor was isolated and sequenced from
the seeds of Sinapis alba L., members of the family Cruciferae.
It was a serine protease inhibitor but did not show any
structural similarity with other identified families of serine
protease inhibitors from plants and it comprised more cysteine
and glycine residues (Menegatti et al., 1985, 1992). In contrary, a
similar type of PI was isolated and characterized from Brassica
napus (rapeseed) (Ceciliani et al., 1994; Ascenzi et al., 1999).
Inhibitors from Secale cereale L. and Ricinus communis L. also
exhibited trypsin inhibitory activity (Odani et al., 1983). A
few reports are available regarding the dual inhibitory activity
(both serine proteases and α- amylase inhibitory activity)
of some inhibitors from Zea mays L. (maize) (Filiz et al.,
2014). Potato inhibitors II has been reported in flowers of
Nicotiana alata Link & Otto (tobacco) (Atkinson et al., 1993).
Serine protease inhibitors were reported in phloem sap of
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FIGURE 4 | Crystal structure of the Bowman-Birk serine protease inhibitor BTCI in complex with a copy of cationic trypsin and three copies of
chymotrypsinogen A. (http://www.ebi.ac.uk/pdbe-srv/view/entry/3ru4/summary.html).
Cucurbita maxima (Kuroda et al., 2001), Arabidopsis and rice
(Oryza sativa cv. Nipponbare; Fluhr et al., 2012) and pumpkin
(Cucurbita maxima; Yoo et al., 2000). Squash Inhibitors have
been reported in cucumber, zucchini (Wieczorek et al., 1985),
watermelon (Citrullus vulgaris), spaghetti squash, red bryony
(Bryonia dioica), figleaf gourd (Otlewski et al., 1987; Polanowski
et al., 1987), Momordica repens (Joubert, 1984), wild cucumber
(Cyclanthera pedata; Kuroda et al., 2001), wax gourd (Benincasa
hispida (Thumb) cogn) (Atiwetin et al., 2006) and in several other
plants of cucurbit family. The small size, structural rigidity and
stability of the members of the squash inhibitor family serve as
potential materials for studying serine protease-protein inhibitor
interaction (Otlewski and Krowarsch, 1996). Cysteine protease
inhibitors were reported in Rice (oryzacystatin) (Abe et al.,
1987a,b), maize (Abe et al., 1992), apple fruit (Ryan et al., 1998),
and several other monocotyledonous as well as dicotyledonous
plants (Pernas et al., 1998; Sakuta et al., 2001). Aspartic protease
inhibitor reported in Anchusa strigosa (Abuereish, 1998) and
squash inhibit pepsin, which is a digestive aspartic protease.
NATURALLY-OCCURRING PLANT
PROTEASE INHIBITORS IN CLINICAL
TRIALS
Many human clinical trials to assess the effect of BBIC have been
finalized or are in progress (Armstrong et al., 2000b; Malkowicz
et al., 2001; Lichtenstein et al., 2008). BBI clinical studies
were carried out in patients (with the approval of Food and
Drug Administration) with oral leukoplakia, prostrate cancer,
gingivitis, ulcerative colitis, lung cancer, anti-inflammation
(Figure 5), multiple sclerosis and encephalomyelitis using BBIC
dose up to 1066 chymotrypsin inhibitory units (C.I.U) per day for
single patient (Sugano, 2006; Table 2). During human trials, even
though the BBI level could not be found in the blood after oral
BBIC medicating, it could be detected in urine (Wan et al., 2000).
Until now, finished clinical trials did not show any toxicity
or neutralizing antibodies against BBIC have been reported
in patients. Armstrong et al. (2000a) reported the safety and
nontoxic nature of BBI and BBIC in phase I trial of BBIC
administered as an oral troche in patients with oral leukoplakia.
The safety of BBIC has also been verified in other human clinical
trials. The Phase-IIa trial of BBIC demonstrated simultaneous
changes in neu protein levels and protease activity in patients
treated with daily doses of 600 C.I.U of BBIC, administered
as 300 C.I.U twice a day as 3 grams of BBIC (Armstrong
et al., 2000b). This Phase-IIb clinical trial of BBIC did not
show many significant differences between placebo and BBIC
treatment. However, both BBIC treatment and placebo group
showed statistically substantial decreases in total lesion area
(Armstrong et al., 2013). Gran et al. (2006) found that BBIC
administration to Lewis rats with experimental autoimmune
encephalomyelitis (EAE) considerably suppressed the disease.
Later, Touil et al. (2008) tested the purified BBI effects
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FIGURE 5 | Schematic representation emphasizing major pharmacological effects of plant protease inhibitors (PPIs). (A) PPIs induces apoptosis of
leukemia cells (healthy red blood cells and leukemia blood cells). (B–D) PPIs showed in vitro anti-carcinogenic effects in initiation (B), proliferation (C), and progression
(D) stages of different types of cancers (gastric, colon, lung, ovarian, and prostate cancers). (E) PPIs as anti-inflammatory agents. (F) The role of PPIs as
anti-coagulant. (G) PPIs active against cardiovascular diseases (plaque formation in a blood vessel). (H) Antibacterial activity of PPIs. (I). Antifungal activity of PPIs.
on clinical and histopathological responses of EAE in two
models (relapsing/remitting EAE in SJL/J mice and chronic
EAE in C57BL/6 mice). Treatment with BBI (1mg/day of
BBI or 3mg/day of BBIC) in both EAE models significantly
effected disease parameters such as onset, severity, weight loss,
inflammation, and demyelination. Moreover, it significantly
reduced the incidence of optic neuritis and prevented loss of
retinal ganglion cells (Touil et al., 2008). Kennedy and Wan
(2002) found that BBIC had a significant inhibitory effect on
the growth and clonogenic survival of BRF-55T, 267B1/Ki-ras,
LNCaP, and PC-3 cells. Dr. Kennedy’s group and others carried
out six human clinical trials for the following issues: cancer
prevention on oral leukoplakia, treatment of benign prostatic
hyperplasia, prostate cancer detection, and treatment, treatment
of ulcerative colitis, gingivitis, or esophagitis (Malkowicz et al.,
2001; Kennedy, 2006). A double-blind, randomized, phase I
clinical trial was conducted in 19 males with Benign prostatic
hyperplasia, which is an initial stage of prostate cancer and lower
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TABLE 2 | Soybean Bowman-Birk inhibitor (BBI) in clinical studies.
Plant protease inhibitors Disease control and Clinical trial phase Dose References
BBI Cancer chemopreventive agent 800 chymotrypsin inhibitor units Armstrong et al., 2000a
Oral Leukoplakia: Phase-I
Oral Leukoplakia: Phase-IIa 200–1066 chymotrypsin inhibitory units Armstrong et al., 2000b
Phase-IIb 300 C.I. Units twice a day Meyskens et al., 2010; Armstrong
et al., 2013
BBI Cancer preventive or anti-inflammatory agent: Phase-I 5 mg/mL Malkowicz et al., 2003
BBI or BBIC Multiple sclerosis Encephalomyelitis 1 mg/day of BBI or 3 mg/day of BBIC Gran et al., 2006; Touil et al., 2008
BBIC Prostatic hyperplasia, 100–800 chymotrypsin inhibitory units Malkowicz et al., 2001; Kennedy and
Wan, 2002; Kennedy, 2006
BBI Ulcerative colitis Lichtenstein et al., 2008
urinary tract symptoms (Malkowicz et al., 2001). This study
demonstrated that BBIC treatment for 6 months reduced levels
of prostate-specific antigen (PSA) which is a clinical marker
for prostate cancer, and prostate volume in patients. Further
clinical studies will be required to determine the potential of
BBIC as prostate cancer chemopreventive agent. BBIC shows
promise to become an effective nontoxic chemopreventive agent
based on results of extensive preclinical studies, and Phase
I and Phase IIa clinical trials. BBIC has dose-related clinical
activity against oral leukoplakia and modulates levels of Neu
(Neu immune histochemical staining intensity for lesions) and
protease activity (Armstrong et al., 2003). Wan et al. (1999a) have
reported a specific substrate hydrolysis methodology to measure
the protease activity of human oral mucosal cells. Eventually
authors have described the connection between neu oncogene
expression and protease activity in patients that are registered for
an oral cancer prevention trial using (BBIC) as the preventive
agent. A completed clinical trial was performed to examine
the safety and possible benefits of BBIC in patients with active
ulcerative colitis (Lichtenstein et al., 2008). BBI demonstrated
anti-inflammatory effects in patients with ulcerative colitis
without toxicity. Investigation and identification of natural plant
protease inhibitors and synthesis of peptidomimetic molecules
have provided various beneficiary compounds that are successful
in using among many human studies. Numerous plant protease
inhibitors are undertaking an additional evaluation in human
clinical trials.
CONCLUSION
New research strategies are now focusing on the understanding
of protease-regulated cascades, along with a specific selection
of targets and improved inhibitor specificity. Many protease
inhibitors have been found in natural sources and also have
been synthesized for clinical uses. Among all, soybean BBI
represent the most expansively studied members of the
Bowman-Birk family, but related BBI from other dicotyledonous
legumes (including Cicer arietinum (chickpea), Phaseolus
vulgaris (common bean), Lens culinaris (lentil), and Pisum
sativum (pea)) and from monocotyledonous grasses (Poaceae)
(including (Triticum aestivum) wheat, Oryza sativa (rice) and
Hordeum vulgare (barley) species), has been well recognized
and characterized. Many pharmaceutical companies are taking
keen interests in several plant protease inhibitors, which are
currently in human trials (Clemente et al., 2010; Clemente and
Arques, 2014). The sequences and crystal structure of many plant
protease inhibitors are now available. But, still only a few are used
in medicine and are in clinical trials (Majumdar, 2013). There are
several advantages of using plant protease inhibitors compared
to synthetic ones. Plant protease inhibitors can also be supplied
through diet (e.g., rice, potato, legumes, soybean, corn, cucurbits,
cereals etc.) by adding some extra plant based food preparations
which will have no side effects on human body. Extensive
research has to be done to find out the possible candidates
of protease inhibitors that have therapeutic importance from
plants. With the growing population and diseases, there is a
need to explore more plant protease inhibitors useful in the
treatment and control of human diseases. This review illustrates
the enormous potential of the protease inhibitors from plant
species in medicine.
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